Harga Saham & Berita untuk GlobeImmune Inc (GBIM)

GlobeImmune, Inc. is a clinical-stage public biopharmaceutical company headquartered in Louisville, Colorado, that develops therapeutic vaccines to treat cancer and infectious diseases. As of August 2014, the company had no marketed products. GlobeImmune’s therapeutic vaccines are developed on the company’s Tarmogen immunotherapy platform. Tarmogens are made from genetically modified yeast that express one or more disease-associated antigens. Tarmogens activate T cells to specifically target and eliminate diseased cells with the same target antigen. The company has partnerships with Celgene and the National Cancer Institute for the development of cancer vaccines. Their collaboration with Gilead for the development of therapeutic vaccines for the treatment of hepatitis B was terminated in November 2016 after the product they were developing failed a clinical trial the year before. With respect to financing in the absence of revenue, the company raised US$17,500,000 through a Series E Preferred Stock offering in January 2010. As of August 2015, GlobeImmune had two therapeutic vaccines in clinical trials, GI-6207 and GI-6301, for the treatment of various cancers. Wikipedia

Tentang GlobeImmune Inc

CEO-

Karyawan22

Didirikan1 Jan 1995

Kantor PusatLouisville, Colorado, Amerika Serikat

Sektor-

Situsglobeimmune.com

Finance

Tanyakan apa saja


Pendapatan
Harga pokok penjualan
Biaya pendapatan
Biaya riset dan pengembangan
Total biaya riset dan pengembangan
Biaya penjualan, umum, dan administrasi
Biaya operasional
Total biaya operasional
Penghasilan operasional
Penghasilan non-operasional lainnya
EBT termasuk item luar biasa
EBT tidak termasuk item luar biasa
Beban pajak penghasilan
Tarif pajak efektif
Biaya operasional lainnya
Penghasilan bersih
Margin laba bersih
Penghasilan per saham
Penghasilan bunga dan investasi
Beban bunga
Beban bunga bersih
Biaya depresiasi dan amortisasi
EBITDA
Keuntungan atau kerugian dari penjualan aset